These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 22506625)
1. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study. Hatoum HT; Lin SJ; Sasane M; Trent JC Curr Med Res Opin; 2012 May; 28(5):805-14. PubMed ID: 22506625 [TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors treatment in the Imatinib era. The role of fair indication. Vendettuoli M; Pironi D; Pontone S; Panarese A; La Gioia G; Arcieri S; Romani AM; Palazzini G; Filippini A Minerva Chir; 2012 Apr; 67(2):165-73. PubMed ID: 22487918 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence]. Li J; Dang YZ; Gao J; Shen L Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778 [TBL] [Abstract][Full Text] [Related]
6. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774 [TBL] [Abstract][Full Text] [Related]
7. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence. Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453 [TBL] [Abstract][Full Text] [Related]
8. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358 [TBL] [Abstract][Full Text] [Related]
9. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk]. Li SX; Li ZY; Zhang LH; Bu ZD; Wu AW; Wu XJ; Zong XL; Shan F; Ji X; Ji JF Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340 [TBL] [Abstract][Full Text] [Related]
10. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334 [TBL] [Abstract][Full Text] [Related]
11. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300 [TBL] [Abstract][Full Text] [Related]
12. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902 [TBL] [Abstract][Full Text] [Related]
17. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]. Zhan WH; Wang PZ; Shao YF; Wu XT; Gu J; Li R; Wan DS; Ding KF; Shi YQ; Yu JR; Lu HS; Zou XM; Bi JW; Sun YH; Lu YF; Chen DD; Zhang XH Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):383-7. PubMed ID: 17043955 [TBL] [Abstract][Full Text] [Related]
19. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730 [TBL] [Abstract][Full Text] [Related]
20. [New prospective on adjuvant treatment for gastrointestinal stromal tumors]. Pan ZZ; Wu XJ Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]